All News

ViewPoints: Regeneron seeing more clearly through regulatory whiplash, but storms still ahead for Eylea
Ref: ViewPoints Desk
Tags: ViewPointsRegeneron Roche Allergan NovartisAMD Marketing & Sales Regulatory AffairsEylea brolucizumab Lucentis
ViewPoints: Opdivo is first I/O through door in SCLC but rivals also knocking
Ref: ViewPoints Desk
Tags: ViewPointsBMS Roche Merck & Co.Lung Cancer FDAMarketing & Sales Medical AffairsOpdivo Keytruda Tecentriq
ViewPoints: Did the FDA just tip its hand on peanut allergy immunotherapies?
Ref: ViewPoints Desk
Tags: ViewPointsAimmune Therapeutics DBV Novartis RocheAllergies FDAClinical Research (R&D) Regulatory AffairsAR101 Viaskin Peanut Xolair
Daily News Round-up Video for August 20, 2018
Ref: Daily News Video
Tags: Daily News VideoRoche Harbour BioMed Kelun-Biotech China Biologic Changsheng CFDA CNDAalecensa A167
Kyowa Hakko Kirin Announces Results of Early Phase 2 Trial of KW-6356 for Parkinson's Disease at IAPRD
Ref: Kyowa Hakko Kirin
Tags: Press ReleaseKyowa Hakko LundbeckParkinson's Clinical Research (R&D) Medical Affairs Corporate Affairs LicensingWorld Congress on Parkinson's Disease and Related DisordersKW-6356
Flexion Therapeutics Announces Presentation of Phase 3 Data at Military Health System Research Symposium
Ref: GlobeNewswire
Tags: Press ReleaseFlexionArthritis Clinical Research (R&D) Medical AffairsMHSRSZilretta
Lantheus Holdings Appoints Robert J. Marshall, Jr. as Chief Financial Officer and Treasurer
Ref: Business Wire
Tags: People NewsLantheus Medical Imaging Corporate Affairs
NIH-led research team develops predictor for immunotherapy response in melanoma
Ref: NIH
Tags: Press ReleaseMelanoma NIH NCIClinical Research (R&D)
American Arbitration Association Panel Finds In Favor Of Adocia In First Phase Of Arbitration Against Eli Lilly
Ref: Adocia
Tags: Press ReleaseAdocia LillyUnited States Corporate Affairs
Promore Pharma Interim report January - June 2018
Ref: Cision
Tags: Press ReleasePromore Pharma Corporate Affairs